Literature DB >> 23768867

Evaluation of TNF superfamily molecules in multiple myeloma patients: correlation with biological and clinical features.

Dorota Lemancewicz1, Lukasz Bolkun, Ewa Jablonska, Agnieszka Kulczynska, Urszula Bolkun-Skornicka, Janusz Kloczko, Janusz Dzieciol.   

Abstract

B-cell activating factor (BAFF), a proliferation-inducing ligand (APRIL) and apoptosis inducing ligand (TRAIL) are members of the tumour necrosis factor (TNF) family. They are the main survival factors for immature, naive and activated B cells. We have analysed BAFF, APRIL and TRAIL serum concentrations in 52 patients with newly diagnosed IgG multiple myeloma and 20 healthy volunteers. The values were significantly higher in the studied patients and advanced diseases, decreasing after chemotherapy, compared to the control group. It was established that BAFF as APRIL (but not TRAIL) correlated with adverse prognostic factors such as IL-6 and lactate dehydrogenase. Furthermore, higher concentrations of APRIL and BAFF (but not TRAIL) predicted a shorter progression free survival, suggesting thereby an important prognostic marker and a possible therapeutic target in myeloma.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  APRIL; BAFF; Multiple myeloma; TRAIL

Mesh:

Substances:

Year:  2013        PMID: 23768867     DOI: 10.1016/j.leukres.2013.05.014

Source DB:  PubMed          Journal:  Leuk Res        ISSN: 0145-2126            Impact factor:   3.156


  12 in total

1.  Novel anti-B-cell maturation antigen antibody-drug conjugate (GSK2857916) selectively induces killing of multiple myeloma.

Authors:  Yu-Tzu Tai; Patrick A Mayes; Chirag Acharya; Mike Y Zhong; Michele Cea; Antonia Cagnetta; Jenny Craigen; John Yates; Louise Gliddon; William Fieles; Bao Hoang; James Tunstead; Amanda L Christie; Andrew L Kung; Paul Richardson; Nikhil C Munshi; Kenneth C Anderson
Journal:  Blood       Date:  2014-02-25       Impact factor: 22.113

2.  Patient-Derived Extracellular Vesicles Proteins as New Biomarkers in Multiple Myeloma - A Real-World Study.

Authors:  Bruna Velosa Ferreira; Emilie Arnault Carneiro; Carolina Pestana; Filipa Barahona; Joana Caetano; Raquel Lopes; Paulo Lúcio; Manuel Neves; Hans Christian Beck; Ana Sofia Carvalho; Rune Matthiesen; Bruno Costa-Silva; Cristina João
Journal:  Front Oncol       Date:  2022-06-21       Impact factor: 5.738

3.  Myelopoiesis dysregulation associated to sustained APRIL production in multiple myeloma-infiltrated bone marrow.

Authors:  T Matthes; T McKee; I Dunand-Sauthier; B Manfroi; S Park; J Passweg; B Huard
Journal:  Leukemia       Date:  2015-03-10       Impact factor: 11.528

Review 4.  B-cell activating factor in the pathophysiology of multiple myeloma: a target for therapy?

Authors:  P J Hengeveld; M J Kersten
Journal:  Blood Cancer J       Date:  2015-02-27       Impact factor: 11.037

Review 5.  Inflammatory and Anti-Inflammatory Equilibrium, Proliferative and Antiproliferative Balance: The Role of Cytokines in Multiple Myeloma.

Authors:  Caterina Musolino; Alessandro Allegra; Vanessa Innao; Andrea Gaetano Allegra; Giovanni Pioggia; Sebastiano Gangemi
Journal:  Mediators Inflamm       Date:  2017-09-26       Impact factor: 4.711

6.  Serum Levels of APRIL Increase in Patients with Glioma, Meningioma and Schwannoma

Authors:  Hamed Fouladseresht; Seyyed Mohyeddin Ziaee; Nasrollah Erfani; Mehrnoosh Doroudchi
Journal:  Asian Pac J Cancer Prev       Date:  2019-03-26

7.  APRIL and sTACI could be predictors of multiorgan dysfunction syndrome in sepsis.

Authors:  Dajana F Lendak; Dunja M Mihajlović; Aleksandra S Novakov-Mikić; Jasmina M Boban; Milan Ubavić; Snežana V Brkić
Journal:  Virulence       Date:  2018-12-31       Impact factor: 5.882

Review 8.  Predictive Role of Immune Profiling for Survival of Multiple Myeloma Patients.

Authors:  Liu Zhaoyun; Fu Rong
Journal:  Front Immunol       Date:  2021-07-05       Impact factor: 7.561

Review 9.  B-Cell Activating Factor as a Cancer Biomarker and Its Implications in Cancer-Related Cachexia.

Authors:  Michal Rihacek; Julie Bienertova-Vasku; Dalibor Valik; Jaroslav Sterba; Katerina Pilatova; Lenka Zdrazilova-Dubska
Journal:  Biomed Res Int       Date:  2015-08-03       Impact factor: 3.411

10.  BAFF and APRIL as TNF superfamily molecules and angiogenesis parallel progression of human multiple myeloma.

Authors:  L Bolkun; D Lemancewicz; E Jablonska; A Kulczynska; U Bolkun-Skornicka; J Kloczko; J Dzieciol
Journal:  Ann Hematol       Date:  2013-10-19       Impact factor: 3.673

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.